Skip to main content

Advertisement

Table 2 Clinical outcome measures at end of treatment and at follow-up

From: Counteracting learned non-use in chronic stroke patients with reinforcement-induced movement therapy

Within-group analysis   Between-group analysis
Mean (SD) - Median 95 % confidence interval for the mean (lower and upper bound)   p-values
  End of treatment Change from p-values Follow-up Change from p-values Change from Change from
  T1 baseline to T1   T2 baseline to T2   baseline to T1 baseline to T2
UE-FM         
EG 38.33 (17.30) – 39 6.00 (6.31) – 4 .008 46.22 (14.96) – 52 13.89 (9.88) – 10 .004   
  [25.04–51.63] [1.15–10.85]   [34.72–57.73] [6.29–21.48]    
        .715 .037
CG 43.22 (12.62) – 44 6.33 (4.50) – 7 .008 41.78 (12.47) – 40 4.89 (4.31) – 5 .016   
  [33.52–52.92] [2.87–9.79]   [32.19–51.36] [1.57–8.20]    
CAHAI         
EG 33.56 (15.08) – 36 1.00 (1.66) – 0 .125 25.11 (16.04) – 42 2.56 (4.64) – 1 .094   
  [21.96–45.15] [-0.27–2.27]   [22.78 – 47.44] [-1.01–6.12]    
        .553 .552
CG 34.22 (14.71) – 43 0.89 (2.37) – 0 .500 34.89 (14.34) – 43 1.56 (3.64) – 0 .250   
  [22.91–45.53] [-0.93–2.71]   [23.87–45.91] [-1.25–4.36]    
BI         
EG 85.56 (10.90) – 88 0.22 (0.67) – 0 1.000 87.78 (8.27) – 90 2.44 (5.18) – 0 .125   
  [77.18–93.93] [-0.29–0.73]   [81.42–94.14] [-1.53–6.42]    
        1.000 .241
CG 91 (6.69) – 90 0.44 (1.33) – 0 1.000 91 (6.69) – 90 0.44 (1.33) – 0 1.000   
  [85.86–96.14] [-0.58–1.47]   [85.86–96.14] [-0.58–1.47]    
Hamilton         
EG 13.89 (9.61) – 8 -0.56 (1.13) – 0 .500 13.67 (9.85) – 8 -0.78 (1.39) – 0 .250   
  [6.50–21.28] [-1.42–0.31]   [6.10–21.24] [-1.85–0.29]    
        .506 .776
CG 10.78 (10.15) – 5 -1.67 (2.83) – 0 .250 11.67 (11.87) – 5 -0.78 (3.93) – 0 .688   
  [2.98–18.58] [-3.84–0.51]   [2.54–20.79] [-3.80–2.24]    
  1. Bold values indicate significant values (p <.05), p-values for within-group analysis were obtained with Wilcoxon signed-rank test, p-values for between-group analysis were obtained with Wilcoxon rank-sum test